Acebutolol in supraventricular arrhythmias

Area of Science:

• Cardiology
• Pharmacology

Background:

• Supraventricular arrhythmias pose a significant clinical challenge.
• Effective and safe treatment options are continuously sought.

Purpose of the Study:

• To evaluate the efficacy of intravenous acebutolol in managing supraventricular arrhythmias.
• To assess the safety and tolerability of acebutolol, particularly in patients with chronic obstructive pulmonary disease (COPD).

Main Methods:

• A study involving 20 patients with various supraventricular arrhythmias.
• Comparison of intravenous acebutolol versus saline placebo.
• Assessment of heart rate reduction and arrhythmia conversion.

Main Results:

• Acebutolol significantly slowed rapid ventricular rates in atrial fibrillation (10/10 patients) and atrial flutter (6/6 patients) compared to saline.
• Frequent premature atrial beats were abolished or reduced by >75% in 2/2 patients treated with acebutolol.
• Acebutolol converted multifocal atrial tachycardia to sinus rhythm and abolished digitalis-induced atrioventricular junctional tachycardia in individual patients.
• Acebutolol was well-tolerated in 5 patients with COPD.

Conclusions:

• Intravenous acebutolol demonstrates significant efficacy in treating supraventricular arrhythmias.
• Acebutolol is a well-tolerated and potentially valuable therapeutic option for these conditions, including in patients with COPD.